Boom Expected in Age-Related Macular Degeneration Market in Future
Registering a CAGR of 7.6% during the forecast period (2016–2022), the global age-related macular degeneration (AMD) market is projected to garner $8.9 billion by 2022, significantly growing from $5.3 billion in 2015. The market is experiencing growth due to the rising geriatric population, growing pipeline for AMD therapeutics, surging chronic disease prevalence, and increasing healthcare expenditure. Age-related macular degeneration is a retinal disorder, which is indicated by changes in the fundus of the eye. It commonly affects the elderly, in which, first, the central vision becomes blurred, which ultimately leads to blindness.
Based on type, the age-related macular degeneration market is bifurcated into wet AMD and dry AMD. Between the two, during the historical period (2012–2015), the larger revenue in the market was generated by the wet AMD type. This type of AMD is caused due to the abnormal growth of blood vessels from the choroid layer, which is situated beneath the macula. It is also known as neovascular macular degeneration, and even though it accounts for only 10–15% of AMD cases, it is expected to be the faster growing category in the forecast period.
Browse report overview and detailed TOC at Age-Related Macular Degeneration Market Demand Forecast
The age-related macular degeneration market is classified into Asia-Pacific, Europe, North America, and Rest of the World, based on region. In 2015, the highest value share in the market was held by the North American region. This was attributed to the rising prevalence of conditions, such as obesity and hypertension. Further, the presence of major pharmaceutical companies supports the regional market growth. In 2022, with high healthcare expenditure of countries in the region, it is predicted to hold more than 90.0% of the market share.
With the rising awareness about the disease, more funding is being allocated in the research and development of AMD therapeutics. This is resulting in the increase in the number of AMD pipeline drugs. Currently, the U.S. Food and Drug Administration has not approved any drug in the age-related macular degeneration (AMD) market for dry age-related macular degeneration. Therefore, the need to investigate more compounds with possible therapeutics properties is rising. Some of the major investigational compounds in the market are Roche/Genentech’s lampalizumab, MacuCLEAR’s MC1101, and Allergan’s brimonide implant.
Therefore, the market for age-related macular degeneration is predicted to register remarkable growth in the forecast period with the rising prevalence of this disease and surging geriatric population.